| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Palmitoyl Tripeptide-1 hydrochloride targets the TGF-β signaling pathway, which is responsible for stimulating dermal fibroblasts to produce extracellular matrix (ECM) proteins. The compound acts on the dermis to affect the synthesis of collagen, fibronectin, and other ECM components. It promotes extracellular matrix synthesis, including collagen and glycosaminoglycan production. The compound positively regulates cell proliferation and connective tissue reconstruction processes. In skin repair, it promotes the synthesis of skin repair proteins.
|
|---|---|
| ln Vitro |
The processes of cell proliferation and connective tissue rebuilding can be positively regulated by palmitoyl tripeptide-1 hydrochloride [1]. During the skin repair process, palmitoyl tripeptide-1 hydrochloride can encourage the synthesis of skin repair proteins [1].
In vitro studies have demonstrated that Palmitoyl Tripeptide-1 hydrochloride promotes extracellular matrix synthesis, including collagen and glycosaminoglycan production. The compound positively regulates cell proliferation and connective tissue reconstruction processes. In skin repair, it promotes the synthesis of skin repair proteins. Palmitoyl tripeptide-1 acts on the TGF-β pathway to stimulate dermal fibroblasts to produce ECM proteins. These in vitro findings support its applications in anti-aging research and cosmetic development. |
| ln Vivo |
In vivo studies of Palmitoyl Tripeptide-1 hydrochloride have demonstrated its anti-aging benefits in human subjects. Some research has shown that this peptide has similar anti-aging benefits to retinol. Subjects reported improvement in elasticity and firmness with decreased fine lines and wrinkles after 8 and 12 weeks of use. The compound promotes extracellular matrix synthesis, reducing wrinkle depth, volume, and density. Topical application restores cell vitality for wrinkle removal. The compound is intended for research and cosmetic use only.
|
| Enzyme Assay |
In vitro receptor binding assays for Palmitoyl Tripeptide-1 hydrochloride typically involve testing its activity on TGF-β signaling in dermal fibroblasts. Cells are treated with varying concentrations of the compound and ECM protein synthesis is assessed. Collagen and fibronectin production is measured by ELISA or Western blotting. Cell proliferation is assessed using standard assays. The compound's purity (99.59%) and identity are confirmed using analytical chemistry methods such as high-performance liquid chromatography and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays for Palmitoyl Tripeptide-1 hydrochloride involve culturing dermal fibroblasts to evaluate its effects on ECM protein synthesis. Cells are treated with varying concentrations of the compound and collagen, fibronectin, and glycosaminoglycan production are measured. TGF-β signaling is assessed by measuring downstream signaling molecules. Cell proliferation is assessed using MTT or similar colorimetric assays. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo human studies for Palmitoyl Tripeptide-1 hydrochloride have been conducted to evaluate its anti-aging effects. Subjects apply formulations containing the compound and skin parameters are assessed. Parameters assessed include wrinkle depth, elasticity, firmness, and hydration. Improvement in elasticity and firmness with decreased fine lines and wrinkles has been reported after 8 and 12 weeks of use. Control groups receiving vehicle alone are included for comparison. All procedures comply with ethical guidelines for human research.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Palmitoyl Tripeptide-1 hydrochloride reflect its nature as a fatty acid-modified peptide. It has a molecular weight of 615.25 and the molecular formula C30H55ClN6O5. The compound is lipophilic due to the palmitoyl moiety,具有良好的皮肤渗透性 (good skin permeability). It is stored under appropriate conditions for research use. Complete pharmacokinetic profiling including absorption, distribution, metabolism, and excretion would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Palmitoyl Tripeptide-1 hydrochloride has been evaluated in the context of its use in cosmetic formulations. The compound is generally considered safe for topical application at recommended concentrations. It has a purity of 99.59%. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research and cosmetic purposes only.
|
| References | |
| Additional Infomation |
Palmitoyl Tripeptide-1 hydrochloride (CAS# 2757690-14-3) is also known as palmitoyl tripeptide-1 HCl. It has the molecular formula C30H55ClN6O5 and a molecular weight of 615.25. The compound is a signal peptide that acts on TGF-β to stimulate dermal fibroblasts to produce ECM proteins. It promotes collagen and glycosaminoglycan synthesis, reducing wrinkle depth. The compound has good wrinkle-removing effect and is used in anti-aging cosmetics.
|
| Molecular Formula |
C30H55CLN6O5
|
|---|---|
| Molecular Weight |
615.247906923294
|
| Exact Mass |
614.392
|
| CAS # |
2757690-14-3
|
| Related CAS # |
Palmitoyl Tripeptide-1;147732-56-7
|
| PubChem CID |
162394438
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
42
|
| Complexity |
738
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
[C@@H](NC(=O)CNC(=O)CCCCCCCCCCCCCCC)(C(=O)N[C@H](C(=O)O)CCCCN)CC1NC=NC=1.Cl
|
| InChi Key |
RJUJGVVVAOCMKF-CCQIZPNASA-N
|
| InChi Code |
InChI=1S/C30H54N6O5.ClH/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-27(37)33-22-28(38)35-26(20-24-21-32-23-34-24)29(39)36-25(30(40)41)17-15-16-19-31;/h21,23,25-26H,2-20,22,31H2,1H3,(H,32,34)(H,33,37)(H,35,38)(H,36,39)(H,40,41);1H/t25-,26-;/m0./s1
|
| Chemical Name |
(2S)-6-amino-2-[[(2S)-2-[[2-(hexadecanoylamino)acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 250 mg/mL (406.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6254 mL | 8.1268 mL | 16.2536 mL | |
| 5 mM | 0.3251 mL | 1.6254 mL | 3.2507 mL | |
| 10 mM | 0.1625 mL | 0.8127 mL | 1.6254 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
